8-K: Citius Pharmaceuticals Faces Imminent Nasdaq Delisting Threat Over Bid Price Non-Compliance

Citius Pharmaceuticals, Inc. has received a Nasdaq delisting notice due to its common stock trading below the $1.00 minimum bid price requirement and plans to appeal the determination by June 5, 2025.

Summary

• Citius Pharmaceuticals, Inc. received a determination letter from the Nasdaq Stock Market on May 29, 2025, notifying the company of non-compliance with the minimum bid price requirement of $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
• The non-compliance is based on the closing bid price of the company's common stock for the prior 33 consecutive business days.
• Due to having effected a reverse stock split within the prior one-year period, the company is not eligible for any standard compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A).
• The company intends to timely request an appeal of the Staff's determination by June 5, 2025, which will stay the suspension and delisting of its common stock pending the Nasdaq Hearings Panel's decision.
• If the company does not timely request a hearing, trading of its common stock is scheduled for delisting at the opening of business on June 9, 2025.
• Citius Pharmaceuticals intends to provide a plan to regain compliance to the Nasdaq Hearings Panel.

Sentiment

Score: 3

Explanation: The notice of delisting non-compliance is a significant negative event, indicating severe stock price underperformance. While the company plans to appeal, the ineligibility for a standard compliance period due to a prior reverse stock split suggests a challenging path forward and highlights underlying issues with investor confidence.

Positives

• The company intends to timely request an appeal by June 5, 2025, which will temporarily stay the delisting process.
• The company plans to provide a plan to regain compliance to the Nasdaq Hearings Panel, indicating an active effort to address the issue.

Negatives

• Received a formal delisting notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share for 33 consecutive business days.
• The company is ineligible for the standard 180-day compliance period due to a reverse stock split effected within the prior one-year period, accelerating the delisting threat.
• There is no assurance that the Nasdaq Hearings Panel will grant the company a compliance period or that it will ultimately meet all applicable requirements for continued listing.

Risks

• The Company may not be successful in its appeal to the Nasdaq Hearings Panel.
• Nasdaq may not grant the Company relief from delisting.
• The Company may not regain compliance with the Bid Price Rule.
• The Company may otherwise fail to meet the requirements for continued listing under the Nasdaq Listing Rules.
• General risks, uncertainties, and important factors discussed under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended September 30, 2024, as updated by its other filings with the Securities and Exchange Commission.

Future Outlook

Citius Pharmaceuticals intends to appeal Nasdaq's determination by June 5, 2025, which will stay the delisting process pending a decision from the Nasdaq Hearings Panel. The company plans to present a compliance plan to the Panel. However, there is no assurance that the appeal will be granted or that the Company will ultimately meet all applicable requirements for continued listing on The Nasdaq Capital Market.

Management Comments

• "The Company intends to timely request an appeal of the Staff's determination by June 5, 2025."
• "The Company intends to provide a plan to regain compliance to the Panel."

Industry Context

Small-cap biotechnology companies frequently face challenges in maintaining stock prices above exchange listing thresholds, particularly during periods of market downturns or if clinical development progress is slower than anticipated. The situation with Citius Pharmaceuticals highlights the ongoing pressure on such companies to demonstrate value and maintain investor confidence, especially when prior measures like reverse stock splits have not yielded sustained compliance.

Stakeholder Impact

• Shareholders face significant risk of delisting, which could lead to reduced liquidity, potential transfer to an over-the-counter market, and further downward pressure on the share price, potentially resulting in a loss of investment.
• Employees may experience increased uncertainty regarding the company's long-term stability and future if delisting occurs.

Next Steps

• Request an appeal of Nasdaq's determination by June 5, 2025.
• Provide a plan to regain compliance to the Nasdaq Hearings Panel.
• Await the Nasdaq Hearings Panel's decision regarding the appeal and compliance plan.

Key Dates

Recommendation

Keywords

Citius Pharmaceuticals, CTXR, Nasdaq, delisting, bid price, non-compliance, reverse stock split, appeal, Nasdaq Capital Market, SEC filing, 8-K